Menu
Your Cart

Apostle MagTouch 2000 Nucleic Acid Extraction Automation System (96-well)

Apostle MagTouch 2000 Nucleic Acid Extraction Automation System (96-well)
Secured Shopping
Best security features
Apostle MagTouch 2000 Nucleic Acid Extraction Automation System (96-well)

For fast extraction and purification of nucleic acids from various kinds of biological samples, in 96 well format.

  1. High quality: Equal or better results compared with other brands. 
  2. Lower cost: Guaranteed 30% - 50% less cost than other brands. 
  3. Faster: One button start; Run time is approximately 40 minutes per 96 samples. 
  4. Safer: Integrated with a UV light for unit interior disinfection. 


  • Cat # A201126-96


Documentation:

ManualApostle-MagTouch-2000-manual.pdf

  • This link directs to download the user manual for Apostle MagTouch 2000 Nucleic Acids Isolation Automation System.

Protocol: The system has been utilized by our clients to extract cell-free DNA and/or RNAs from various volumes of liquid samples.  The system is also easily programmable to adapt with various laboratory settings and needs.  Some example protocols are listed below. 


Application Note: Application-Note-Apostle-Viral-RNA-Isolation-System.pdf

  • This links directs to an Application Note on the Apostle COVID-19 Viral RNA Extraction System, applied in the effective detection of SARS-CoV-2 in over 8 million clinical samples by our clients. Using Apostle system, limit of Detection (LoD) of the downstream detection system of our customer is documented at 3.6 NDU/uL published on the FDA website. The sensitivity and specificity is 99.9% and 99.9% at 3 copies/uL, respectively, published on our customer’s website.


Inclusion in US FDA IVD EUA - Molecular Diagnostic Tests for SARS-CoV-2

Apostle RNA extraction method is included in a US FDA EUA authorized SARS-CoV-2 molecular diagnostic test: Fulgent COVID-19 by RT-PCT Test.


More information: Product Data page

$48,000.00
Using Apostle MiniMax cfDNA Isolation Technology a recent clinical study in 2821 myeloid or lymphoid neoplasm patients shows that liquid biopsy using targeted NGS is reliable in detecting chromosomal structural abnomalities in myeloid neoplasms. The study supports the use of liquid biopsy for early diagnosis and monitoring of patients with myeloid neoplasms. Read article